Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxegol for Prevention of Post-operative Constipation in Spinal Surgery
NCT02946580Phase 4Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2017
- Primary completion
- Feb 2018
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of naloxegol in opioid-induced constipation (OIC) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Time to First Post-operative Spontaneous Bowel Movement at 6 days. Started Jan 2017; status: terminated.
02
Drugs
naloxegol
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT02946580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02946580.